ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRON vs JNJ // NET PROFIT MARGIN

Disc Medicine Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IRON 5 — JNJ 8
▲ NET PROFIT MARGIN LEADER: JNJ
net-margins
28.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRON VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRON JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 41.00% 67.90% -26.90 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -27.50% 25.50% -53.00 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -4.93% 2.97% -7.90 JNJ /fcf-yield <GO>
Operating Margin -22.90% 34.70% -57.60 JNJ /operating-margins <GO>
Net Profit Margin ACTIVE -20.60% 28.50% -49.10 JNJ /net-margins <GO>
Revenue Growth (YoY) 16.50% 6.00% +10.50 IRON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 5.59 +20.41 IRON /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.60% 7.20% -0.60 IRON /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.8 60.4 +4.45 IRON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.90 1.08 -0.18 JNJ /macro-sensitivity <GO>
Forward P/E Multiple 20.0x 23.0x -3.00 IRON /forward-pe <GO>
Enterprise Scale & Market Cap $3.68B $662.49B -$658.81B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRON REV JNJ REV IRON GROSS % JNJ GROSS % IRON FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% -$181.3M $19.70B
FY 2024 $0 $88.82B — 69.1% -$94.4M $19.84B
FY 2023 $0 $85.16B — 44.0% -$73.5M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRON // BETA 0.90
JNJ // BETA 1.08